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sensitivity and speciﬁcity of 69% and 71% of CT scan and 45% and 
65% of MRI respectively does not provide sufﬁcient informations for 
these patients. Modern techniques as positron emission tomography 
(FDG-PET or FDG-PET/CT) and endobronchial (EBUS) or endo-
scopic (EUS) ultrasound guided ﬁne-needle aspiration (FNA) have 
also been used for mediastinal staging. In a prospective study with 
202 patients found Gonzalez-Strawinski and al. that current FDG-PET 
technology alone does not appear to be sufﬁcient to warrant reliable 
treatment changes or the avoidance of mediastinoscopy in the evalu-
ation of patients with NSCLC. FDG-PET results have been shown to 
be difﬁcult to interpret after radiotherapy and the best time to repeat it 
still remains unproved. An inherent problem of the FDG contrast is that 
inﬂamed tissue will absorb it, so that granulomatous or inﬂammatory 
mediastinal disease or cases of obstructive malignant processes resulted 
to difﬁculty identifying mediastinal malignancy with FDG-PET. In our 
series we found that patients after induction chemoradiotherapy showed 
a strongly FDG accumulation due to inﬂammatory reaction of radiated 
mediastinal tissue, so that the number of false postive cases ranged by 
20%. Hellwig et al reported about the high negative predictive value in 
mediastinal restaging of FDG-PET so that only low values of lowstan-
dardized uptakes allows for omission of RM .
EBUS and EUS guided FNA are promising technique for staging of 
solid lesions and lymph nodes located adjacent to the trachea, the main 
bronchi and the esophagus but is not comparable to mediastinoscopy 
or RM . Selection of the patients for EUS or EBUS-FNA was based 
on computed tomographic scanning and with that only in patients with 
pathological radiological ﬁndings. Both techniques are used to assese 
the entire mediastinun or to stage predominantly only one nodal sta-
tion, but they are not used for the systematical standarized exploration 
of individual nodes as performed by mediastinoscopy. Moreover, the 
echogenic characteristics alone of a node might not be as reliable after 
radiation as they are before. In our experience representative material 
from scarred and ﬁbrotic lymph nodes after chemoradiotherapy is dif-
ﬁcult to be taken, the number of false positive results in the cytologic 
examination of FNA should be not underestimated. Particularly for 
local advanced disease and neoadjuvant treatment a histological tissue 
diagnosis must still be obtained, so that it is unlikely that the addition 
of transtracheal, transbronchial, and endoscopic ultrasonographically 
guided FNA will sufﬁciently rule out disease relative to the histologic 
results achieved from mediastinoscopy. EBUS and EUS are supple-
mentary diagnostical tools and may contribute to improve staging, 
especially in cases with metastasis in the hilar nodes or the mediastinal 
nodes which could not be reached by CM or RM.
Some investigators have focused on an early intensiﬁcation of preop-
erative downstaging by bimodality induction including chemotherapy 
as well as radiation therapy before surgery. In these patients the clinical 
classsiﬁcation especially the mediastinal staging after the induction 
treatment must yield the possible maximal accuraccy. Bueno et al 
and Voltolini et al pointed out in two separate reports that nodal stage 
after induction therapy for stage IIIA lung cancer determines patient 
survival. Downstaged patients to N0 status survived 59% at 3 years 
and 35.8% at 5 years respectively. However as have been proved the 
persistence of lymph node involvement after induction treatment has 
a discouraging prognosis with 3 years survival of 0% in the ﬁrst and 
5 years survival of 9% in the second study. This data support surgical 
resection only for downstaged patients and that a direct effort should be 
made to improve the accuracy of restaging before resection. Because 
of this, our oncological group considered to performe the RM in order 
to re-evaluate the mediastinum taken biopsies and verifying the nodal 
status in all patients entered into two complete phase II and one phase 
III trial and selecting patients for resection. Technical aspects of RM 
are well described in previous reports. The presence of peritracheal ad-
hesions makes the exploration more complex than by the initial medias-
tinoscopy. Analogous to other reports we did´t have a perioperative or 
postoperative mortality. A low rate of morbidity was observed (4.2 %) 
concient with reported results from other series. Furthermore additional 
operations due to intraoperative complications were not necessary. The 
incidence of recurrent nerve palsy was in accordance with the numbers 
after ﬁrst mediastinoscopy. 
We conclude that RM is a feasible and safe surgical procedure for 
restaging of patients with primary locally advanced, recurrent or second 
primary lung cancer. There are no mortality, the perioperative com-
plications rate are very low. In patients after induction treatment RM 
proved to be less sensitive than the ﬁrst procedure because of adhe-
sions and ﬁbrotic tissue. Because of the higher sensitivity, speciﬁcity 
and accuracy in compare to radiological investigations, FDG-PET and 
ultrasound guided FNA remains RM despite the technical complexity 
the criterion standard for mediastinal restaging in patients with local 
advanced lung cancer and induction treatment. 
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The Tumour, Node, Metastases (TNM) system for the classiﬁcation 
of malignant tumours was developed by Pierre Denoix in a series of 
papers between 1943 and 1952 (1;2). In 1953 it was accepted by the 
International Union Against Cancer (UICC) Committee on Tumour 
Nomenclature and Statistics. In 1968 it appeared in the 1st edition of 
their Classiﬁcation of Malignant Tumours. In 1973 the American Joint 
Committee on Cancer (AJCC) Task Force on Lung Cancer accepted the 
recommendations of Drs. Mountain, Carr and Anderson for a clini-
cal staging system of lung cancer (3). The following year the UICC 
accepted these proposals, unifying the 2 staging systems, in their 2nd 
edition of the TNM Classiﬁcation of Malignant Tumours.
The AJCC recommendations were based upon a database which con-
sisted of 1,712 cases of non-small cell lung cancer (NSCLC) diagnosed 
at least 4 years before the analysis of results. Nearly all of the descrip-
tors used today in staging lung cancer were established in that relatively 
small database, including the only size cut off for T descriptors (that of 
3 cms which distinguishes T1 from T2 tumours), the impact of speciﬁc 
areas of local invasion (visceral pleura, diaphragm, chest wall and the 
mediastinum and its contents), the proximal bronchoscopic extent of 
disease, pleural effusion and the extent of atelectasis or pneumonitis. 
In this version the highest “T” descriptor was 3, that for “N” was 2 and 
the highest stage was stage III.
Since that pioneering work there have been 4 more revisions. The size 
of the database on which these changes were made has increased, to 
5319 in the 5th revision (4), the review process has become progres-
sively more “International” and a few new descriptors have been added, 
resulting in the expansion of the “T” category to 4, the “N” category 
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to 3 and the number of stages to IV. However, the database remained 
predominately based upon a surgical series from one centre in the USA.
With the retirement of Dr. Clifton Mountain the International Associa-
tion for the Study of Lung Cancer (IASLC) felt there was a need to 
continue his work and an opportunity for it, as the only global body 
to include specialists in all of the ﬁelds of diagnosis, treatment and 
research into lung cancer, to create an International database of cases 
treated by all modalities of care worldwide. With ﬁnances provided 
through a restricted educational grant by Eli Lilly and Company, data 
transfer, collection and analysis by Cancer Research And Biostatistics 
(CRAB) and the generous support of 46 databases in over 19 countries 
we have amassed data on over 100,000 cases of lung cancer treated 
between 1990 and 2000 (5). At a later stage, additional funding was 
obtained through a competitive process within the AJCC. An initial 
sift excluded those cases with inadequate data on staging or survival, 
those in which cell-type was unclear or inappropriate, those with 
recurrent disease rather than a new primary cancer and those outside 
our intended study period. There remained 81, 021 cases suitable for 
further analysis, consisting of 13,290 cases of small-cell lung cancer 
(SCLC) and 67,731 cases of non-small cell lung cancer (NSCLC). This 
data came from clinical trials, tumour registries, International registries, 
surgical registries, series treated by surgery and other modalities and 
consortia. All modalities of care were represented but understand-
ably the largest proportion were treated by surgery (41%) followed by 
chemotherapy (23%) and radiotherapy (11%), the rest being treated by 
combined modality care or best supportive care. European centres con-
tributed 58% of the NSCLC cases followed by North America (21%), 
Asia (14%) and Australia (7%). In the NSCLC cases 53,646 had data 
on clinical staging. There were 33,933 with pathological staging data 
and in 20,006 there was data on both cTNM and pTNM.
The analysis of this data was completed at the end of 2006 and the 
subsequent recommendations for the 7th edition of the TNM Classiﬁca-
tion were submitted to the UICC in December 2006. The recommenda-
tions, with supplementary suggestions regarding the TNM staging of 
SCLC and carcinoid tumours, a new concept in nodal classiﬁcation and 
comments on the role of additional prognostic factors will be submitted 
to the AJCC in June 2007. These recommendations will be published in 
the Journal of Thoracic Oncology in a series of discussion papers com-
mencing in July 2007 and will form the basis of the subsequent talks in 
this session. We have already started to prepare for the next phase of the 
project which will extend the retrospective database and create a pro-
spective database for future revisions. This will enable us to look further 
into some issues that could not be addressed in a retrospective fashion.
Our recommendations are now subject to the internal review processes 
of the UICC and AJCC, which include review by National cancer com-
mittees and an International panel of experts. Once these discussions 
are complete the 7th edition will be published in January 2009. 
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Introduction
In 1999 the International Association for the Study of Lung Cancer 
(IASLC) initiated an international staging project with the objective to 
analyse a large international database of patients with lung cancer in 
order to study the T, the N and the M components of the current lung 
cancer classiﬁcation and staging system, and eventually recommend 
revisions to the present edition (6th) of the TNM classiﬁcation. If the 
resulting changes were accepted by the Union Internationale Contre le 
Cancer (UICC) and the American Joint Committee on Cancer (AJCC), 
they would appear in the 7th edition of the TNM classiﬁcation for lung 
cancer, due to be published in 2009 (1). 
This paper is presented by the T-descriptors Subcommittee on behalf of 
the International Staging Committee, Cancer Research and Biostatis-
tics, Observers to the Committee, and Participating Institutions.
Material and method
Data on 100,869 patients were collected in the international database 
and analysed by Cancer Research and Biostatistics (CRAB). The 
T-descriptors subcommittee and CRAB analysed a subset of 18,198 
patients with non-small cell lung cancer (NSCLC) who had a complete 
set of cTNM or pTNM and sufﬁcient T-descriptor details to support the 
assigned T-stage. These included 180 patients with M1 tumours with 
additional nodule(s) in a different ipsilateral lobe from the primary 
tumour lobe. In the populations of patients with complete cTNM0 and 
pTNM0, 5,760 and 15,234, respectively, had sufﬁcient information on 
T-descriptors. Too few patients had speciﬁc information on descriptors 
of higher Ts, and most T2 descriptors (except for tumour size) and all 
T3 and T4 descriptors (except for additional nodule(s)) could not be 
analysed. The present study is focussed, therefore, on tumour size and 
additional nodule(s) in the tumour-bearing lobe or different ipsilateral 
lobe. For the speciﬁc analysis of tumour size, the population of patients 
with pT1-2N0M0 completely resected (R0) tumours was selected, but 
the identiﬁed cutpoints were also explored in the population of patients 
with any N tumours and incomplete resections. This larger popula-
tion of patients was also used to analyse the tumours with additional 
nodule(s) and their relations to T3, T4 and M1 tumours. A learning set 
of approximately 2/3 (4,891 patients) was used to develop the optimal 
size cutpoints that were then tested in the validation set of the remain-
ing 1/3 (2,589 patients). In the derivation of tumour size cutpoints, the 
running log-rank statistic produced by each hypothetical cutpoint in 
the pN0M0R0 learning set was graphed against tumour size, and the 
tumour size which coincided with the highest log-rank statistic was 
chosen as the optimal cutpoint, after rounding to the nearest whole cm. 
The results were internally validated by geographic region and type of 
database, and externally validated using the Serveillance, Epidemiol-
ogy and End Results (SEER) registry (2). 
